Preview Mode Links will not work in preview mode

Apr 5, 2021

Featuring an interview with Dr Natalie S Callander, including the following topics:

  • Treatment of high-risk smoldering multiple myeloma (MM) with carfilzomib, lenalidomide and dexamethasone followed by maintenance lenalidomide: A Phase II clinical and correlative study (0:00)
  • Early versus late autologous stem cell transplant for newly diagnosed MM: Long-term follow-up analysis of the IFM 2009 trial (3:27)
  • Updated analysis of the GRIFFIN trial: Daratumumab with lenalidomide, bortezomib and dexamethasone for patients with transplant-eligible newly diagnosed MM (14:48)
  • Results from the ANDROMEDA trial evaluating bortezomib, cyclophosphamide and dexamethasone with or without daratumumab for newly diagnosed amyloid light chain (AL) amyloidosis (17:20)
  • Interim analysis of the IKEMA trial evaluating depth of response and response kinetics with isatuximab added to carfilzomib and dexamethasone for relapsed/refractory (R/R) MM (21:23)
  • KarMMa trial: Efficacy and safety of idecabtagene vicleucel in elderly patients with R/R MM (27:55)
  • CARTITUDE-1: Phase Ib/II study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed CAR (chimeric antigen receptor) T-cell therapy, for R/R MM (37:21)
  • Activity and safety of the bispecific antibodies talquetamab and cevostamab (BFCR4350A) in patients with R/R MM (42:21)
  • ANCHOR trial: Updated efficacy and safety of melflufen with either dexamethasone/daratumumab or dexamethasone/bortezomib for R/R MM (47:25)
  • Iberdomide in combination with dexamethasone, daratumumab or both and with dexamethasone/bortezomib for patients with R/R MM (52:39)
  • ALGONQUIN trial: Efficacy and tolerability of belantamab mafodotin with pomalidomide/dexamethasone for patients with R/R MM (55:33)
  • Selinexor in combination with pomalidomide and dexamethasone for R/R MM (57:29)
  • Phase II SWOG-S1702 study of isatuximab for patients with previously treated AL amyloidosis (1:00:17)
  • Safety and efficacy of CAEL-101 in patients with AL amyloidosis on a Phase II dose selection study (1:02:02)
  • Five-year follow-up of ibrutinib with rituximab for Waldenström macroglobulinemia (WM): Final analysis from the Phase III iNNOVATETM study (1:04:06)
  • Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide as first-line treatment for WM: Results of a randomized Phase II trial (1:07:11)
  • Roles of zanubrutinib and acalabrutinib for WM (1:09:40)

CME information and select publications